Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older

Takaaki Konuma, Nobuhiro Tsukada, Junya Kanda, Naoyuki Uchida, Yuju Ohno, Shigesaburo Miyakoshi, Heiwa Kanamori, Michihiro Hidaka, Toru Sakura, Makoto Onizuka, Naoki Kobayashi, Masashi Sawa, Tetsuya Eto, Yoshiko Matsuhashi, Koji Kato, Tatsuo Ichinohe, Yoshiko Atsuta, Koichi Miyamura

    Research output: Contribution to journalArticle

    16 Citations (Scopus)

    Abstract

    Older recipient and donor age were associated with higher incidences of severe graft-versus-host disease (GVHD) and mortality after allogeneic hematopoietic stem cell transplantation from matched sibling donors (MSDs) and matched unrelated donors. Since a lower incidence of severe GVHD is advantageous in unrelated cord blood transplantation (CBT), a higher incidence of GVHD using older MSDs could be overcome using cord blood for older patients. We retrospectively analyzed Japanese registration data of 2,091 patients with acute myeloid leukemia, acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome aged 50 years or older who underwent MSD bone marrow transplantation (BMT) (n=319), MSD peripheral blood stem cell transplantation (PBSCT) (n=462), or unrelated CBT (n=1,310) between 2007 and 2012. Median age of MSD was 56 (range, 38-74) years. Compared with CBT, the risk of developing extensive chronic GVHD was higher after BMT (hazard ratio [HR], 2.00; P=0.001) or PBSCT (HR, 2.38; P<0.001), and transplant-related mortality was lower after BMT (HR, 0.61; P<0.001) or PBSCT (HR, 0.63; P<0.001). Relapse rates were not significant difference between three groups. Although overall mortality was lower after BMT (HR, 0.67; P<0.001) or PBSCT (HR, 0.75; P=0.002) compared with CBT, the rates of a composite endpoint of GVHD-free, relapse-free survival (GRFS) were not significant difference between three groups. These data showed that MSDs remain the best donor source for older patients, but CBT led to similar GRFS to BMT and PBSCT.

    Original languageEnglish
    Pages (from-to)E284-E292
    JournalAmerican Journal of Hematology
    Volume91
    Issue number5
    DOIs
    Publication statusPublished - May 1 2016

    Fingerprint

    Fetal Blood
    Siblings
    Peripheral Blood Stem Cell Transplantation
    Bone Marrow
    Tissue Donors
    Graft vs Host Disease
    Transplants
    Bone Marrow Transplantation
    Transplantation
    Recurrence
    Mortality
    Incidence
    Unrelated Donors
    Survival
    Peripheral Blood Stem Cells
    Hematopoietic Stem Cell Transplantation
    Myelodysplastic Syndromes
    Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Acute Myeloid Leukemia

    All Science Journal Classification (ASJC) codes

    • Hematology

    Cite this

    Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. / Konuma, Takaaki; Tsukada, Nobuhiro; Kanda, Junya; Uchida, Naoyuki; Ohno, Yuju; Miyakoshi, Shigesaburo; Kanamori, Heiwa; Hidaka, Michihiro; Sakura, Toru; Onizuka, Makoto; Kobayashi, Naoki; Sawa, Masashi; Eto, Tetsuya; Matsuhashi, Yoshiko; Kato, Koji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Miyamura, Koichi.

    In: American Journal of Hematology, Vol. 91, No. 5, 01.05.2016, p. E284-E292.

    Research output: Contribution to journalArticle

    Konuma, T, Tsukada, N, Kanda, J, Uchida, N, Ohno, Y, Miyakoshi, S, Kanamori, H, Hidaka, M, Sakura, T, Onizuka, M, Kobayashi, N, Sawa, M, Eto, T, Matsuhashi, Y, Kato, K, Ichinohe, T, Atsuta, Y & Miyamura, K 2016, 'Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older', American Journal of Hematology, vol. 91, no. 5, pp. E284-E292. https://doi.org/10.1002/ajh.24340
    Konuma, Takaaki ; Tsukada, Nobuhiro ; Kanda, Junya ; Uchida, Naoyuki ; Ohno, Yuju ; Miyakoshi, Shigesaburo ; Kanamori, Heiwa ; Hidaka, Michihiro ; Sakura, Toru ; Onizuka, Makoto ; Kobayashi, Naoki ; Sawa, Masashi ; Eto, Tetsuya ; Matsuhashi, Yoshiko ; Kato, Koji ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Miyamura, Koichi. / Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. In: American Journal of Hematology. 2016 ; Vol. 91, No. 5. pp. E284-E292.
    @article{fa715a055cac4d15ab0c0ffd5f488595,
    title = "Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older",
    abstract = "Older recipient and donor age were associated with higher incidences of severe graft-versus-host disease (GVHD) and mortality after allogeneic hematopoietic stem cell transplantation from matched sibling donors (MSDs) and matched unrelated donors. Since a lower incidence of severe GVHD is advantageous in unrelated cord blood transplantation (CBT), a higher incidence of GVHD using older MSDs could be overcome using cord blood for older patients. We retrospectively analyzed Japanese registration data of 2,091 patients with acute myeloid leukemia, acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome aged 50 years or older who underwent MSD bone marrow transplantation (BMT) (n=319), MSD peripheral blood stem cell transplantation (PBSCT) (n=462), or unrelated CBT (n=1,310) between 2007 and 2012. Median age of MSD was 56 (range, 38-74) years. Compared with CBT, the risk of developing extensive chronic GVHD was higher after BMT (hazard ratio [HR], 2.00; P=0.001) or PBSCT (HR, 2.38; P<0.001), and transplant-related mortality was lower after BMT (HR, 0.61; P<0.001) or PBSCT (HR, 0.63; P<0.001). Relapse rates were not significant difference between three groups. Although overall mortality was lower after BMT (HR, 0.67; P<0.001) or PBSCT (HR, 0.75; P=0.002) compared with CBT, the rates of a composite endpoint of GVHD-free, relapse-free survival (GRFS) were not significant difference between three groups. These data showed that MSDs remain the best donor source for older patients, but CBT led to similar GRFS to BMT and PBSCT.",
    author = "Takaaki Konuma and Nobuhiro Tsukada and Junya Kanda and Naoyuki Uchida and Yuju Ohno and Shigesaburo Miyakoshi and Heiwa Kanamori and Michihiro Hidaka and Toru Sakura and Makoto Onizuka and Naoki Kobayashi and Masashi Sawa and Tetsuya Eto and Yoshiko Matsuhashi and Koji Kato and Tatsuo Ichinohe and Yoshiko Atsuta and Koichi Miyamura",
    year = "2016",
    month = "5",
    day = "1",
    doi = "10.1002/ajh.24340",
    language = "English",
    volume = "91",
    pages = "E284--E292",
    journal = "American Journal of Hematology",
    issn = "0361-8609",
    publisher = "Wiley-Liss Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older

    AU - Konuma, Takaaki

    AU - Tsukada, Nobuhiro

    AU - Kanda, Junya

    AU - Uchida, Naoyuki

    AU - Ohno, Yuju

    AU - Miyakoshi, Shigesaburo

    AU - Kanamori, Heiwa

    AU - Hidaka, Michihiro

    AU - Sakura, Toru

    AU - Onizuka, Makoto

    AU - Kobayashi, Naoki

    AU - Sawa, Masashi

    AU - Eto, Tetsuya

    AU - Matsuhashi, Yoshiko

    AU - Kato, Koji

    AU - Ichinohe, Tatsuo

    AU - Atsuta, Yoshiko

    AU - Miyamura, Koichi

    PY - 2016/5/1

    Y1 - 2016/5/1

    N2 - Older recipient and donor age were associated with higher incidences of severe graft-versus-host disease (GVHD) and mortality after allogeneic hematopoietic stem cell transplantation from matched sibling donors (MSDs) and matched unrelated donors. Since a lower incidence of severe GVHD is advantageous in unrelated cord blood transplantation (CBT), a higher incidence of GVHD using older MSDs could be overcome using cord blood for older patients. We retrospectively analyzed Japanese registration data of 2,091 patients with acute myeloid leukemia, acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome aged 50 years or older who underwent MSD bone marrow transplantation (BMT) (n=319), MSD peripheral blood stem cell transplantation (PBSCT) (n=462), or unrelated CBT (n=1,310) between 2007 and 2012. Median age of MSD was 56 (range, 38-74) years. Compared with CBT, the risk of developing extensive chronic GVHD was higher after BMT (hazard ratio [HR], 2.00; P=0.001) or PBSCT (HR, 2.38; P<0.001), and transplant-related mortality was lower after BMT (HR, 0.61; P<0.001) or PBSCT (HR, 0.63; P<0.001). Relapse rates were not significant difference between three groups. Although overall mortality was lower after BMT (HR, 0.67; P<0.001) or PBSCT (HR, 0.75; P=0.002) compared with CBT, the rates of a composite endpoint of GVHD-free, relapse-free survival (GRFS) were not significant difference between three groups. These data showed that MSDs remain the best donor source for older patients, but CBT led to similar GRFS to BMT and PBSCT.

    AB - Older recipient and donor age were associated with higher incidences of severe graft-versus-host disease (GVHD) and mortality after allogeneic hematopoietic stem cell transplantation from matched sibling donors (MSDs) and matched unrelated donors. Since a lower incidence of severe GVHD is advantageous in unrelated cord blood transplantation (CBT), a higher incidence of GVHD using older MSDs could be overcome using cord blood for older patients. We retrospectively analyzed Japanese registration data of 2,091 patients with acute myeloid leukemia, acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome aged 50 years or older who underwent MSD bone marrow transplantation (BMT) (n=319), MSD peripheral blood stem cell transplantation (PBSCT) (n=462), or unrelated CBT (n=1,310) between 2007 and 2012. Median age of MSD was 56 (range, 38-74) years. Compared with CBT, the risk of developing extensive chronic GVHD was higher after BMT (hazard ratio [HR], 2.00; P=0.001) or PBSCT (HR, 2.38; P<0.001), and transplant-related mortality was lower after BMT (HR, 0.61; P<0.001) or PBSCT (HR, 0.63; P<0.001). Relapse rates were not significant difference between three groups. Although overall mortality was lower after BMT (HR, 0.67; P<0.001) or PBSCT (HR, 0.75; P=0.002) compared with CBT, the rates of a composite endpoint of GVHD-free, relapse-free survival (GRFS) were not significant difference between three groups. These data showed that MSDs remain the best donor source for older patients, but CBT led to similar GRFS to BMT and PBSCT.

    UR - http://www.scopus.com/inward/record.url?scp=84962182290&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84962182290&partnerID=8YFLogxK

    U2 - 10.1002/ajh.24340

    DO - 10.1002/ajh.24340

    M3 - Article

    C2 - 26910296

    AN - SCOPUS:84962182290

    VL - 91

    SP - E284-E292

    JO - American Journal of Hematology

    JF - American Journal of Hematology

    SN - 0361-8609

    IS - 5

    ER -